Clinical trial • Phase I • Oncology
Durvalumab for Hepatocellular carcinoma
Phase I trial of Durvalumab for Hepatocellular carcinoma. 10 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Hepatocellular carcinoma
- Trial Stage
- Phase I
- Drug Modality
- Vaccine|Other|Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 21-10-2024
- First CTIS Authorization Date
- 11-11-2024
Trial design
Phase I trial across 1 site in Italy.
- Target Sample Size
- 10
Recruitment
- Planned Sample Size
- 10
- Recruitment Window Months
- 40
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 10
Italy
- Earliest CTIS Part Ii Submission Date
- 26-09-2024
- Latest Decision Or Authorization Date
- 11-11-2024
- Processing Time Days
- 46
- Number Of Sites
- 1
- Number Of Participants
- 10
Sites
- Site Name
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Department Name
- Oncologia Medica Melanoma Immunoterapia Oncologica e Terapie Innovative
- Principal Investigator Name
- Paolo Ascierto
- Principal Investigator Email
- p.ascierto@istitutotumori.na.it
- Contact Person Name
- Paolo Ascierto
- Contact Person Email
- p.ascierto@istitutotumori.na.it
- Number Of Participants
- 10
Sponsor
Primary sponsor
- Full Name
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Italy
Investigational products
- Investigational Product Name
- IMA970A
- Modality
- Vaccine
- Investigational Product Name
- Montanide
- Modality
- Other
- Investigational Product Name
- Durvalumab
- Active Substance
- Durvalumab
- Modality
- Monoclonal antibody
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.